Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 33NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Genitourinary 7Breast 5Tumor-Agnostic 4CNS 4Other solid neoplasm 3Head & Neck 3Dermatologic 3Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Follicular 1Constriction, Pathologic 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Therapeutics × Lymphoid × Clear all
NCT05149755 2026-05-19

Evolutâ„¢ EXPAND TAVR II Pivotal Trial

Medtronic Cardiovascular

Phase NA Active not recruiting
650 enrolled
Lymphoid

Constriction, Pathologic, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡